![]() |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|
|
![]() As of its last market close, VIVO had a market capitalization of approximately $1.1 billion USD. The company had a trailing twelve-month revenue of approximately $235 million USD and a net income of approximately $31 million USD. VIVO's stock price had a 52-week range of $13.31 - $22.92 USD and was trading at approximately $16.39 USD at the time of its last market close. Meridian Bioscience is focused on expanding its product offerings and increasing its market share in its core markets. The company is also exploring new markets and applications for its products, particularly in the point-of-care and companion diagnostics markets. Investing in VIVO carries risks, including risks associated with changes in technology and customer preferences, as well as risks associated with competition and market conditions. Additionally, Meridian Bioscience is subject to regulatory and geopolitical risks, which could impact its financial performance. Investors should carefully consider these risks before making any investment decisions.
|
||||||||||||
|
||||||||||||
|
||||||||||||
|